Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapies that modulate the body's natural immune system to treat patients with chronic inflammatory diseases, viral infections, and cancer. The company is headquartered in Paris, France, and is known for its innovative approach to drug development.
History[edit | edit source]
Abivax was founded in 2013 with the aim of leveraging the immune system to address unmet medical needs. Since its inception, the company has been involved in the development of several promising drug candidates.
Research and Development[edit | edit source]
Abivax's research and development efforts are centered around its proprietary technology platforms, which include small molecules and biologics designed to modulate the immune response.
ABX464[edit | edit source]
One of Abivax's lead drug candidates is ABX464, a small molecule with anti-inflammatory properties. It is being investigated for the treatment of ulcerative colitis, Crohn's disease, and other inflammatory conditions. ABX464 works by enhancing the expression of a specific microRNA, miR-124, which plays a role in regulating inflammation.
ABX196[edit | edit source]
Another key candidate is ABX196, an immune enhancer being developed for the treatment of hepatocellular carcinoma and other cancers. ABX196 is a synthetic glycolipid agonist of iNKT cells, which are a type of immune cell involved in tumor surveillance.
Clinical Trials[edit | edit source]
Abivax is actively conducting clinical trials to evaluate the safety and efficacy of its drug candidates. The company has reported promising results from its Phase 2 trials of ABX464 in patients with ulcerative colitis, demonstrating significant clinical remission rates.
Partnerships and Collaborations[edit | edit source]
Abivax collaborates with various academic institutions and industry partners to advance its research and development programs. These collaborations are crucial for accessing new technologies and expanding the potential applications of its drug candidates.
Future Directions[edit | edit source]
The company aims to continue advancing its pipeline through clinical development and regulatory approval processes. Abivax is committed to addressing significant unmet medical needs and improving patient outcomes through innovative therapies.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
